Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.58 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | TGM2 | P21980 | 9/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | ALB | P02768 | 1/20 | 0.35 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.33 |
| ▸ | SPHK1 | Q9NYA1 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12465059 | 0.96 | ZDHHC20 (0.53) | ZDHHC20ZDHHC2ALDH1A1TSHRMAPK1 | |
| SCHEMBL30705730 | 0.92 | TSHR (0.50) | ZDHHC20ZDHHC2ALDH1A1TSHRMAPK1 | |
| Agmatine SCHEMBL955625 | 0.88 | ALOX15 (0.47) | ZDHHC20ZDHHC2ALDH1A1TSHRMAPK1 | |
| SCHEMBL632264 | 0.85 | ZDHHC20 (0.75) | ZDHHC20ZDHHC2ALDH1A1TSHRMAPK1 | |
| SCHEMBL29041295 | 0.83 | ZDHHC20 (0.58) | ZDHHC20ZDHHC2ALDH1A1TSHRMAPK1 | |
| SCHEMBL28414712 | 0.83 | ZDHHC20 (0.58) | ZDHHC20ZDHHC2ALDH1A1TSHRMAPK1 | |
| SCHEMBL28424912 | 0.83 | ZDHHC20 (0.58) | ZDHHC20ZDHHC2ALDH1A1TSHRMAPK1 | |
| SCHEMBL8405507 | 0.83 | ZDHHC20 (0.79) | ZDHHC20ZDHHC2ALDH1A1TSHRMAPK1 | |
| SCHEMBL1592093 | 0.83 | ZDHHC20 (0.79) | ZDHHC20ZDHHC2ALDH1A1TSHRMAPK1 | |
| SCHEMBL58169 | 0.83 | ZDHHC20 (0.79) | ZDHHC20ZDHHC2ALDH1A1TSHRMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10017461-B2 | Method of making ligand functionalized substrates | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2018-07-10 | — | — | US | disclosed |
| US-20170217880-A1 | METHOD OF MAKING LIGAND FUNCTIONALIZED SUBSTRATES | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY | 2017-08-03 | — | — | US | disclosed |
| EP-1923064-B1 | Use of amine polymer for lowering serum glucose | GENZYME CORP (US) | 2017-06-28 | — | — | EP | disclosed |
| US-9650470-B2 | Method of making ligand functionalized substrates | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2017-05-16 | — | — | US | disclosed |
| US-20140364519-A1 | METHOD OF MAKING LIGAND FUNCTIONALIZED SUBSTRATES | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY | 2014-12-11 | — | — | US | disclosed |
| EP-1675818-B1 | METHOD FOR SYNTHESIS OF ACRYLAMIDO AGMATINE | GE HEALTHCARE BIO SCIENCES AB (SE) | 2014-12-03 | — | — | EP | disclosed |
| US-8846203-B2 | Method of making ligand functionalized substrates | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2014-09-30 | — | — | US | disclosed |
| EP-2522692-B1 | Ligand monomers and copolymers made therewith | 3M INNOVATIVE PROPERTIES CO (US) | 2014-06-18 | — | — | EP | disclosed |
| US-20140087445-A1 | METHOD OF MAKING LIGAND FUNCTIONALIZED SUBSTRATES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2014-03-27 | — | — | US | disclosed |
| US-8652582-B2 | Method of making ligand functionalized substrates | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2014-02-18 | — | — | US | disclosed |
| WO-2002085380-A1 | METHOD FOR TREATING GOUT AND REDUCING SERUM URIC ACID | GELTEX PHARMACEUTICALS, INC. (US) | 2002-10-31 | — | — | WO | disclosed |
| US-20010051660-A1 | Method for reducing oxalate | GELTEX PHARMACEUTICAL, INC. (US) | 2001-12-13 | — | — | US | disclosed |
| US-6281252-B1 | ADMINISTERING A ALIPHATIC AMINE POLYMER; THERAPY FOR KIDNEY STONES | GELTEX PHARMACEUTICAL, INC. | 2001-08-28 | — | — | US | disclosed |
| US-6177478-B1 | USING AN AMINE POLYMER; PREVENT KIDNEY STONES | GELTEX PHARMACEUTICALS, INC. | 2001-01-23 | — | — | US | disclosed |
| EP-1044008-A1 | USE OF ALIPHATIC POLYAMINES FOR REDUCING OXALATE | GELTEX PHARMACEUTICALS, INC. (US) | 2000-10-18 | — | — | EP | disclosed |
| US-5985938-A | Method for reducing oxalate | GELTEX PHARMACEUTICALS, INC. (US) | 1999-11-16 | — | — | US | disclosed |
| WO-1999022744-A1 | USE OF ALIPHATIC POLYAMINES FOR REDUCING OXALATE | GELTEX PHARMACEUTICALS, INC. (US) | 1999-05-14 | — | — | WO | disclosed |
| WO-1998042355-A1 | PHOSPHATE-BINDING POLYMERS COMBINED WITH A CALCIUM SUPPLEMENT FOR ORAL ADMINISTRATION | GELTEX PHARMACEUTICALS, INC. (US) | 1998-10-01 | — | — | WO | disclosed |
| EP-0831857-A2 | PHOSPHATE-BINDING POLYMERS FOR ORAL ADMINISTRATION | GELTEX PHARMACEUTICALS, INC. (US) | 1998-04-01 | — | — | EP | disclosed |
| WO-1996039156-A2 | PHOSPHATE-BINDING POLYMERS FOR ORAL ADMINISTRATION | GELTEX PHARMACEUTICALS, INC. (US) | 1996-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10017461-B2 | Method of making ligand functionalized substrates | SPR, SELPLG, SIGLEC7 | ZDHHC20 3224/4885ZDHHC2 3371/4885ALDH1A1 1262/4885 |
| US-20010051660-A1 | Method for reducing oxalate | OAT, OTC, XDH | ZDHHC20 4024/4885ZDHHC2 4250/4885ALDH1A1 2135/4885 |
| US-20140364519-A1 | METHOD OF MAKING LIGAND FUNCTIONALIZED SUBSTRATES | SPR, SELPLG, SIGLEC7 | ZDHHC20 3224/4885ZDHHC2 3371/4885ALDH1A1 1262/4885 |
| US-20170217880-A1 | METHOD OF MAKING LIGAND FUNCTIONALIZED SUBSTRATES | SPR, SELPLG, SIGLEC7 | ZDHHC20 3224/4885ZDHHC2 3371/4885ALDH1A1 1262/4885 |
| US-20140087445-A1 | METHOD OF MAKING LIGAND FUNCTIONALIZED SUBSTRATES | SPR, SELPLG, SIGLEC7 | ZDHHC20 3224/4885ZDHHC2 3371/4885ALDH1A1 1262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.